IP Library Assignment 053122/0081
Patent Assignment
Reel/Frame 053122/0081

Change of Address for Assignee

Recorded: 2020-07-02 Pages: 35
Assignor
Assignee
OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KFT
LEVENTE UTCA 14/A, CSOMAD, 2161, HUNGARY
Covered Properties (45)
Osmotic Device Containing Pseudoephedrine and an H1ANTAGONIST
Patent: 6,613,357 →
Application: 09/725,655 →
Publication: US 2002/0102305
Osmotic Device Containing Venlafaxine and an Anti-Psychotic Agent
Patent: 6,572,890 →
Application: 09/728,276 →
Publication: US 2001/0048943
Osmotic Device Having a Preformed Passageway That Increases in Size
Patent: 6,599,284 →
Application: 09/728,859 →
Publication: US 2002/0099361
Osmotic Device Within an Osmotic Device
Patent: 6,491,949 →
Application: 09/755,827 →
Publication: US 2002/0035357
Drug Delivery Device Containing Oseltamivir and an H1 Antagonist
Patent: 6,605,302 →
Application: 09/907,486 →
Publication: US 2003/0044457
Laser Drilling System and Method
Patent: 6,809,288 →
Application: 10/153,226 →
Publication: US 2003/0189030
Osmotic Device Containing Venlafaxine and an Anti-Psychotic Agent
Patent: 7,008,641 →
Application: 10/377,173 →
Publication: US 2003/0219483
Drug Delivery Device Containing Neuraminidase Inhibitor and an H1 Antagonist
Patent: 7,208,176 →
Application: 10/619,720 →
Publication: US 2004/0062801
Osmotic Device Containing Pseudoephedrine and an H1 Antagonist
Patent: 7,147,870 →
Application: 10/643,011 →
Publication: US 2004/0131685
Rupturing Controlled Release Device Having a Preformed Passageway
Patent: 8,029,822 →
Application: 10/851,866 →
Publication: US 2005/0008702
Laser Drilling System and Method
Patent: 7,569,794 →
Application: 10/957,428 →
Publication: US 2005/0145605
Osmotic Device Containing a Venlafaxine Salt and a Salt Having an Ion in Common
Patent: 8,293,799 →
Application: 11/010,829 →
Publication: US 2005/0163851
Osmotic Device Containing Amantadine and an Osmotic Salt
Patent: 8,252,331 →
Application: 11/287,882 →
Publication: US 2006/0159763
Dual Controlled Release Osmotic Device
Patent: 8,241,667 →
Application: 11/321,736 →
Publication: US 2006/0177510
Dual Controlled Release Dosage Form
Patent: 8,329,217 →
Application: 11/355,315 →
Publication: US 2006/0204578
Triple Combination Release Multi-Layered Tablet
Patent: 8,685,451 →
Application: 12/141,677 →
Publication: US 2008/0299197
Rupturing Controlled Release Device Comprising a Subcoat
Patent: 8,637,080 →
Application: 12/146,069 →
Publication: US 2009/0004229
Osmotic Device Containing Amantadine and an Osmotic Salt
Patent: 8,574,626 →
Application: 13/551,755 →
Publication: US 2013/0115249
Dual Controlled Release Dosage Form
Patent: 8,591,947 →
Application: 13/625,658 →
Publication: US 2013/0108693
Triple Combination Release Multi-layered Tablet
Patent: 9,833,412 →
Application: 14/188,150 →
Publication: US 2014/0302141
Controlled Release Dosage Form
Patent: 9,579,289 →
Application: 15/048,743 →
Publication: US 2016/0263043
Controlled Release Dosage Form
Patent: 9,585,843 →
Application: 15/132,972 →
Publication: US 2016/0243067
Controlled Release Dosage Form
Patent: 9,655,858 →
Application: 15/146,525 →
Publication: US 2016/0243072
Dose-Dumping Resistant Controlled Release Dosage Form
Patent: 9,707,217 →
Application: 15/424,134 →
Controlled Release Dosage Form
Patent: 9,801,841 →
Application: 15/492,714 →
Publication: US 2017/0216236
Dose-Dumping Resistant Controlled Release Dosage Form
Patent: 9,827,234 →
Application: 15/624,075 →
Dose-Dumping Resistant Controlled Release Dosage Form
Patent: 9,855,258 →
Application: 15/624,209 →
Dose-Dumping Resistant Controlled Release Dosage Form
Application: 15/656,237 →
Publication: US 2018/0221360
Controlled Release Dosage Form with Enhanced Pharmacokinetics
Application: 15/673,781 →
Publication: US 2017/0340570
Controlled Release Dosage Form
Application: 15/673,985 →
Publication: US 2017/0340592
Controlled Release Dosage Form
Application: 15/680,434 →
Publication: US 2017/0354625
Composition and Method for Treating Neurological Disease
Application: 15/898,143 →
Composition and Method for Treating Neurological Disease
Application: 15/898,148 →
Controlled Release Dosage Form
Application: 15/919,422 →
Publication: US 2018/0200214
Controlled Release Dosage Form
Application: 15/919,436 →
Publication: US 2018/0200215
Controlled Release Dosage Form with Enhanced Pharmacokinetics
Application: 16/178,865 →
Publication: US 2019/0070121
Controlled Release Dosage Form
Application: 16/212,093 →
Publication: US 2019/0111013
Composition and Method for Treating Neurological Disease
Application: 16/241,631 →
Publication: US 2019/0247327
Composition and Method for Treating Neurological Disease
Application: 16/241,636 →
Publication: US 2019/0247328
Composition and Method for Treating Neurological Disease
Application: 16/250,608 →
Publication: US 2019/0247329
Composition and Method for Treating Neurological Disease
Application: 16/250,686 →
Publication: US 2019/0247330
Dose-Dumping Resistant Controlled Release Dosage Form
Application: 16/269,126 →
Publication: US 2019/0167654
Controlled Release Dosage Form
Application: 16/270,837 →
Publication: US 2019/0167618
Controlled Release Dosage Form
Application: 16/380,716 →
Publication: US 2019/0255005
Controlled Release Dosage Form
Application: 16/798,652 →
Publication: US 2020/0188341
Related Assignments (9)
Other recorded transfers of the patents in this record — the chain of ownership.
Transfer of Right to Make, Use, Sell, Offer to Sell for Nifedipine Feb 4, 2010
From: OSMOTICA CORP.
To: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
Reel/Frame 023892/0674 →
Transfer of Right to Make, Use, Sell, Offer to Sell for Oxybutynin Feb 4, 2010
From: OSMOTICA CORP.
To: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
Reel/Frame 023892/0723 →
Corrective Assignment to Correct the Name of the Assignee on the Recordation Sheet to Osmotica Pharmaceutical Corp. Previously Recorded on Reel 023892 Frame 0674. Assignor(S) Hereby Confirms the Transfer of Right to Make, Use, Sell, Offer to Sell for Nifedipine. Feb 8, 2010
From: OSMOTICA CORP.
To: OSMOTICA PHARMACEUTICAL CORP.
Reel/Frame 023905/0766 →
Corrective Assignment to Correct the Name of the Assignee on the Recordation Sheet to Osmotica Pharmaceutical Corp. Previously Recorded on Reel 023892 Frame 0723. Assignor(S) Hereby Confirms the Transfer of Right to Make, Use, Sell, Offer to Sell for Oxybutynin. Feb 8, 2010
From: OSMOTICA CORP.
To: OSMOTICA PHARMACEUTICAL CORP.
Reel/Frame 023905/0752 →
Assignee Change of Address Nov 20, 2013
From: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
To: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
Reel/Frame 031692/0741 →
Security Interest Feb 3, 2016
From: OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KORLÁTOLT FELELOSSÉGU TÁRSASÁG
To: CIT BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 037656/0777 →
Security Interest Aug 27, 2021
From: AVION PHARMACEUTICALS, LLC; SOVEREIGN PHARMACEUTICALS, LLC; ACELLA HOLDINGS, LLC
To: CIBC BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 057310/0385 →
Release of Security Interest Aug 28, 2021
From: CIT BANK, N.A., AS COLLATERAL AGENT
To: OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KORLÁTOLT FELELOSSÉGU TÁRSASÁG
Reel/Frame 057319/0873 →
Assignment of Assignor's Interest Sep 28, 2021
From: OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KORLÁTOLT FELELOSSÉGU TÁRSASÁG
To: ACELLA HOLDINGS, LLC
Reel/Frame 057627/0758 →